Novo Nordisk, a global healthcare company, has promoted four corporate vice presidents to senior vice presidents. Effective March 1, 2013, the following members of the U.S. executive team will assume the title of senior vice president in their respective areas: Andy Ajello, U.S. national diabetes sales; Camille Lee, U.S. diabetes marketing; Alan Moses, MD, global chief medical officer; and Anne Phillips, MD, U.S. clinical, medical and regulatory affairs.

Ajello has been in the pharmaceutical industry for nearly 20 years. He joined Novo Nordisk in March 2001 and currently leads the national diabetes sales strategy and the company's approximately 3,200 person field sales organization. During Ajello’s 12 years with the company, he has been widely recognized for developing and motivating a high-performing sales team. His responsibilities include oversight of the entire diabetes sales organization, including managed markets sales, field force operations and strategic sales initiatives.

Lee has more than 25 years of experience in the industry. She joined Novo Nordisk in 1985 as a sales representative in Southern California, and through her tenure with the company has held national and international positions of increasing authority in the areas of marketing, strategic launch planning and sales management. Over the past six years, Lee has built a strong diabetes marketing team of 365 people that has been recognized internally and externally for their best-in-class initiatives. She currently has oversight for the marketing of all in-line and future brands, as well as the organization's diabetes educator program.

Moses joined Novo Nordisk in 2004 from Harvard Medical School and the Joslin Diabetes Center as associate vice president for clinical research and medical affairs, endocrinology, and in 2007 was named chief medical officer for North America. One year later, he was appointed to global chief medical officer. Moses is involved in the full spectrum of Novo Nordisk's diverse diabetes work from drug discovery to addressing the implications of diabetes for patients, healthcare professionals and healthcare systems.

Phillips brings more than 20 years of medical, research and regulatory experience to her role. She currently leads an integrated drug development, medical, regulatory and safety team of more than 550 people, and plays a key role in advancing Novo Nordisk's diabetes and biopharmaceutical clinical development pipelines. Phillips is responsible for the efficient development and delivery of compounds in clinical trials, including product lifestyle and in-licensed compounds.